Our final objective is to develop an adoptive therapy with tolerogenic donor-specific Tr1
cells in T1D patients undergoing pancreatic islet transplantation (Tx). The achievement of
this objective depends by the availability of an immunosuppressive treatment (IS) compatible
with the survival, function, and expansion of the transferred Tr1 cells. For this purpose the
investigators design a CNI-free single-group, phase 1-2 trial excluding the ATG or anti-CD25
induction therapy after the 1st islet infusion